Underlying features of prostate cancer—statistics, risk factors, and emerging methods for its diagnosis
Prostate cancer (PCa) is the most frequently occurring type of malignant tumor and a leading
cause of oncological death in men. PCa is very heterogeneous in terms of grade …
cause of oncological death in men. PCa is very heterogeneous in terms of grade …
The rise of PSMA ligands for diagnosis and therapy of prostate cancer
A Afshar-Oromieh, JW Babich… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The prostate-specific membrane antigen (PSMA) has received increased consideration
during the past few years as an excellent target for both imaging and therapy of prostate …
during the past few years as an excellent target for both imaging and therapy of prostate …
Targeted radionuclide therapy of human tumors
SV Gudkov, NY Shilyagina, VA Vodeneev… - International journal of …, 2015 - mdpi.com
Targeted radionuclide therapy is one of the most intensively developing directions of nuclear
medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy …
medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy …
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
L Scarpa, S Buxbaum, D Kendler, K Fink… - European journal of …, 2017 - Springer
Introduction A targeted theragnostic approach based on increased expression of prostate-
specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients …
specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients …
Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer
EL Guryev, NO Volodina… - Proceedings of the …, 2018 - National Acad Sciences
We report combined therapy using upconversion nanoparticles (UCNP) coupled to two
therapeutic agents: beta-emitting radionuclide yttrium-90 (90Y) fractionally substituting …
therapeutic agents: beta-emitting radionuclide yttrium-90 (90Y) fractionally substituting …
Targeted radionuclide therapy: an evolution toward precision cancer treatment
H Jadvar - American Journal of Roentgenology, 2017 - Am Roentgen Ray Soc
OBJECTIVE. This article reviews recent developments in targeted radionuclide therapy
(TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine …
(TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine …
Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection
RB Den, D George, C Pieczonka… - American journal of …, 2019 - journals.lww.com
Bone metastases are common in men with metastatic castrate-resistant prostate cancer
(mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in> 90% of …
(mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in> 90% of …
VCAM-1 targeted alpha-particle therapy for early brain metastases
Background Brain metastases (BM) develop frequently in patients with breast cancer.
Despite the use of external beam radiotherapy (EBRT), the average overall survival is short …
Despite the use of external beam radiotherapy (EBRT), the average overall survival is short …
Clinical perspectives of theranostics
S Okamoto, T Shiga, N Tamaki - Molecules, 2021 - mdpi.com
Theranostics is a precision medicine which integrates diagnostic nuclear medicine and
radionuclide therapy for various cancers throughout body using suitable tracers and …
radionuclide therapy for various cancers throughout body using suitable tracers and …
Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions
J Wang, J Zang, H Wang, Q Liu, F Li, Y Lin… - Clinical nuclear …, 2019 - journals.lww.com
Aim Combined 68 Ga-PSMA-617 PET imaging and 177 Lu-PSMA-617 therapy is a precise
targeted theranostic approach for patients with metastatic castration-resistant prostate …
targeted theranostic approach for patients with metastatic castration-resistant prostate …